- Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
This study looks at a new medicine called garadacimab for people with hereditary angioedema (HAE). It aims to see if the treatment is safe and helps prevent HAE attacks over a long time. Researchers are checking how many side effects people have and if attacks become less frequent.
For: Hereditary angioedemaNetherlands · Germany · Hungary - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age
This study is testing a new medicine, garadacimab, for children aged 2-11 with hereditary angioedema (HAE). It aims to see how safe the medicine is, how it moves through the body, and if it helps prevent HAE attacks. Researchers will also check for any side effects.
For: Hereditary angioedema (HAE)Germany · Italy